DOI:
10.1055/s-00000059
Pneumologie
LinksClose Window
References
Yang JC, Shih JY, Su WC et al.
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.
Lancet Oncol 2012;
13: 539-548
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.